Federal Register · Regulatory notice
Notice Pursuant to the National Cooperative Research and Production Act of 1993-R Consortium, Inc.
A Notice notice explicitly mentions the company. Read the cited text for its role.
Follow NVO- Became public
- Nov 10, 2026
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 6:39 PM EST
Why this is connected
The source explicitly mentions NOVO NORDISK A S. A mention alone does not establish a financial benefit.
Source evidence
Read the source excerpt or record
in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Gilead Sciences, Inc., Foster City, CA, has been added as a party to this venture. Also, Lander Analytics, New York, NY; and Novo Nordisk A/S, Hovedstaden, KINGDOM OF DENMARK, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and R Consortium intends to file additional written notifications disclosing all changes in membership. On September 15, 2015, R Consortium filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on October 2, 2015 (80 FR 59815). The last notification was filed with the Department on April 24, 2026. A notice was published in the Federal Register pursuant to section 6(b) of the Act on July 22, 2026 (91 FR 46163). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2026-22894 Filed 11-9-26; 8:45 am] BILLING CODE;P
Congressional trading in NVO
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Sep 25, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
$1K–$15K · Traded Sep 10, 2026 · disclosed Sep 25, 2026
- Sep 25, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
Sold (partial) Novo Nordisk A/S NVO
$1K–$15K · Traded Aug 31, 2026 · disclosed Sep 25, 2026
- Sep 17, 2026$1K–$15K
Rep. Scott Franklin (R-FL-18)
$1K–$15K · Traded Aug 26, 2026 · disclosed Sep 17, 2026
- Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
$15K–$50K · Traded Mar 30, 2026 · disclosed Jul 21, 2026 · filed 113 days later
Committee overlap: HELP - Nov 21, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
$1K–$15K · Traded Oct 31, 2025 · disclosed Nov 21, 2025 · Spouse
- Nov 21, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
$1K–$15K · Traded Oct 30, 2025 · disclosed Nov 21, 2025 · Spouse
- Nov 21, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
$1K–$15K · Traded Oct 30, 2025 · disclosed Nov 21, 2025 · Spouse
- Oct 22, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
$1K–$15K · Traded Sep 11, 2025 · disclosed Oct 22, 2025 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.